着床前遺伝学的検査市場：技術、提供、手順タイプ、用途、エンドユーザー別- 世界予測2024-2030年

着床前遺伝学的検査市場規模は、2023年に7億2,840万米ドルと推定され、2024年には8億2,906万米ドルに達し、CAGR 14.56％で2030年には18億8,628万米ドルに達すると予測されています。

着床前遺伝学的検査（PGT）とは、着床前の胚に影響を及ぼす染色体異常を検出するために使用される技術を指します。PGTは、体外受精（IVF）法における着床前の胚の遺伝子異常を早期に検出することを可能にする重要なサービスであり、子孫に遺伝性疾患を引き継ぐリスクを大幅に低減し、IVFの成功率を向上させる。PGTの主な応用分野には、単発性疾患、染色体異常、ミトコンドリア病の特定、潜在的な兄弟姉妹のためのヒト白血球抗原（HLA）マッチングなどがあります。ライフスタイルの変化による不妊率の上昇や、夫婦の間で親になる選択が遅れていることから、PGT技術の開発が必要とされています。体外受精治療を推進する政府のイニシアティブは、多くの拡大機会を生み出しています。しかし、体外受精治療やPGT処置に伴う高額な費用は、潜在的なエンドユーザーにとって大きな抑止力となり得る。PGTを取り巻く倫理的な懸念や、体外受精治療に対する保険適用範囲の狭さが、PGTサービスの採用を妨げています。大手バイオテクノロジー企業は、倫理的・規制的課題に立ち向かう取り組みを急速に拡大し、道徳的・倫理的問題を考慮した技術を生み出しています。次世代シークエンシング（NGS）や非侵襲的着床前検査といった新たなアプローチは、この技術の成長に大きな可能性をもたらす新たな技術です。

テクノロジー染色体異常や単一遺伝子障害を検出する次世代シーケンスの進歩

比較ゲノムハイブリダイゼーション（CGH）は、2つのサンプルのDNAを比較することで、染色体の不均衡を検出するために採用されています。着床前の胚の染色体異常を検出し、体外受精のための健康な胚の選択に役立ちます。蛍光in situハイブリダイゼーション（FISH）は、蛍光プローブを用いて細胞内の染色体上の特定のDNA配列を可視化し、マッピングする技術です。異数性や転座を含む染色体異常を検出することができます。次世代シーケンシング（NGS）は、大量のDNAを迅速かつ正確に配列決定できることから、着床前遺伝学的検査のための強力なツールです。ポリメラーゼ連鎖反応（PCR）は、広く使用されている分子生物学的手法であり、解析のために特定のDNA配列を増幅し、単遺伝性疾患を検出することができます。一塩基多型（SNP）は、ゲノム内の一塩基レベルでの変異を評価するもので、遺伝性疾患の保因者を同定したり、がんを含む多因子疾患のリスクを評価するために使用されます。

提供：プロセス条件を最適化し、正確な結果を導き出すための多様なオファリングの活用

機器は、胚の正確かつ効率的な遺伝子スクリーニングを可能にするため、PGTプロセスにおいて重要な役割を果たします。主な機器には、次世代シーケンサー（NGS）、定量PCR（qPCR）システム、蛍光in situハイブリダイゼーション（FISH）分析装置などがあります。NGSは高スループットシーケンス能力と幅広い検出範囲を提供し、単一遺伝子異常や染色体異常の検出に適しています。PGTに使用される試薬や消耗品は、遺伝子検査に必要な各種キット、プローブ、バッファー、酵素、溶液などで構成されます。プローブは特定の染色体異常を検出するために不可欠であり、緩衝液は最適な増幅条件のための適切な条件を提供します。ソフトウェアとサービスは、遺伝子検査結果の信頼できるデータ管理、分析、解釈、報告を確実にするため、PGTに不可欠な要素です。ユーザーフレンドリーなインターフェイス、バリアント検出のための正確なアルゴリズム、バリアント注釈のための包括的なデータベース、安全なデータ保存オプションなどを中心に、ニーズに応じた嗜好が展開されます。

手順着床前遺伝子診断（PGD）の普及が進み、遺伝性疾患のリスクが減少します。

着床前遺伝子診断（PGD）は、着床・妊娠前に診断された胚の遺伝子変異や染色体異常を同定することができる特殊な処置です。PGDの主な目的は、嚢胞性線維症、ハンチントン病、筋ジストロフィーなどの特定の遺伝性疾患の発症リスクを低減することです。着床前遺伝学的スクリーニング（PGS）は、異数性染色体（PGT-A）のための着床前遺伝学的検査と呼ばれ、着床前の胚の染色体異数性または不均衡を検出します。PGSは、正しい染色体数の胚を同定することにより、流産や死産、ダウン症やその他の染色体異常のリスクを減らし、妊娠の成功確率を高めることを目的としています。

応用異数性障害の着床前遺伝学的検査の広範な使用

異数性障害とは、細胞内の染色体数の異常により、ダウン症候群、エドワーズ症候群、パタウ症候群などの遺伝的障害を引き起こす疾患です。着床前異数性遺伝子検査（PGT-A）は、着床前に染色体異常のある胚を同定し、妊娠が成功する確率を高めます。着床前遺伝学的検査による性別識別は、夫婦が家族のバランスを考えたり、性連鎖障害を避けるために子供の性別を選択することを可能にします。ヒト白血球抗原（HLA）タイピングは、幹細胞移植や臓器移植の際に、ドナーとレシピエントの組織型を一致させる。着床前HLAタイピングは、適合する組織型を持つ胚を同定し、血液疾患や免疫系不全を持つ兄弟姉妹の移植を成功に導く可能性があります。染色体構造異常は、欠失、重複、再配列を含む染色体構造の変化を伴う。さらに、X連鎖性疾患はX染色体上の遺伝子の変異によって引き起こされ、女性よりも男性に深刻な影響を及ぼします。

エンドユーザー：正確な診断と効果的な治療のため、ヘルスケア研究機関でPGTの採用が増加中

着床前遺伝学的検査は様々なヘルスケア施設で広く利用されており、臨床研究で成果を上げています。受託研究・製造機関（CRMO）は、製品の開発、製造、商品化において重要な役割を果たす主要な組織です。これらの組織は、コアコンピタンスに集中する一方で、品質管理、規制基準の遵守、コスト効率を確保するために、サービスのアウトソーシングを好んでいます。同様に、クライオバンクは精子、卵子、胚などの生物学的サンプルを将来の使用のために極低温で保存する機関です。着床前遺伝学的検査は、体外受精や顕微授精のような移植手術の前に、保存されたサンプルの遺伝的生存性を確保するために、クライオバンクにとって極めて重要です。病院、診断ラボ、サービスプロバイダーは、着床前遺伝学的検査の技術を使った正確な診断と効果的な治療を通じて、患者のケアに貢献しています。研究機関や学術機関は、最先端の研究、技術開発、学際的なコラボレーションを通じて、着床前遺伝学的検査の革新と進歩を推進する上で重要な役割を果たしています。これらの機関は、着床前遺伝学的検査法の精度を高めるために、次世代シーケンス（NGS）のような新しい技術の開発に注力しています。

地域別の洞察

南北アメリカでは、ライフスタイルの変化による不妊率の上昇や遺伝子検査に対する意識の高まりから、着床前遺伝学的検査（PGT）のニーズが高いです。整備されたヘルスケアインフラ施設と有利な償還政策により、南北アメリカでは不妊治療を求めるカップルにとってPGTサービスがより利用しやすくなっています。この地域の企業は強力な研究開発能力を有し、政府の支援がこの分野の技術革新を後押ししています。アジアは、PGTサービスによる体外受精のような高度な不妊治療技術の提供が改善され、医療ツーリズムが拡大し、費用対効果の高い治療オプションを求める外国人患者を惹きつけているため、PGTの大きな好機的市場として台頭してきています。欧州は、ヘルスケア研究に対する政府資金の増加や、欧州各国における体外受精の普及などの要因により、世界のPGT市場に大きく貢献しています。さらに、遺伝子検査を取り巻く厳格な規制の枠組みは、PGTサービスを実施する際の品質管理と倫理的配慮を保証しています。この地域の主要企業は、着床前遺伝学的検査の実践における技術的進歩に大きく貢献しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは着床前遺伝学的検査市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、着床前遺伝学的検査市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.着床前遺伝学的検査市場の市場規模および予測は？

2.着床前遺伝学的検査市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.着床前遺伝学的検査市場の技術動向と規制枠組みは？

4.着床前遺伝学的検査市場における主要ベンダーの市場シェアは？

5.着床前遺伝学的検査市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 胎児異常の発生率が高く、健康で正常な胚移植が必要である
    • 不妊率の増加と不妊治療クリニックの世界の増加
    • 早期診断アプローチの拡大と遺伝性疾患治療に対する政府支援の増加
  • 抑制要因
    • PGTに伴う制限とリスク
  • 機会
    • 着床前遺伝子解析分野における技術の進歩
    • 着床前遺伝学的検査分野における新興スタートアップエコシステムと投資
  • 課題
    • PGTの倫理的制約と誤用
• 市場セグメンテーション分析
  • 技術：染色体異常や単一遺伝子疾患を検出するための次世代シーケンシングの進歩
  • 提供内容：多様なサービスを活用してプロセス条件を最適化し、正確な結果を導きます
  • 手順：遺伝性疾患のリスクを減らすために着床前遺伝子診断（PGD）手順の導入を増やす
  • 応用：異数性疾患に対する着床前遺伝学的検査の幅広い利用
  • エンドユーザー：正確な診断と効果的な治療のために、ヘルスケア調査機関におけるPGTの採用が増加
• 市場動向分析
  • 南北アメリカ全域で革新的な着床前遺伝子ソリューションを展開する大手企業や新興企業の存在
  • 政府の支援策と不妊率の増加により、アジア太平洋地域での着床前遺伝学的検査の採用が強調されました。
  • 欧州全域での体外受精における着床前遺伝学的検査の採用増加と中東およびアフリカにおける世界プレーヤーの拡大の可能性
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 着床前遺伝学的検査市場：技術別

• 比較ゲノムハイブリダイゼーション
• 蛍光in-situハイブリダイゼーション
• 次世代シーケンシング
• ポリメラーゼ連鎖反応
• 一塩基多型

第7章 着床前遺伝学的検査市場：提供別

• 機器
• 試薬・消耗品
• ソフトウェアとサービス

第8章 着床前遺伝学的検査市場手順の種類別

• 着床前遺伝子診断
• 着床前遺伝子スクリーニング

第9章 着床前遺伝学的検査市場：用途別

• 異数性
• 性別の認識
• HLAタイピング
• 単一遺伝子疾患
• 染色体構造異常
• X連鎖疾患

第10章 着床前遺伝学的検査市場：エンドユーザー別

• 契約調査・製造組織
• クライオバンク
• 病院、診断ラボ、サービスプロバイダー
• 調査室および学術機関

第11章 南北アメリカの着床前遺伝学的検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の着床前遺伝学的検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの着床前遺伝学的検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • サーモフィッシャーがIon ReproSeq PGT-AキットとIon AmpliSeq倍数性キットを発表
  • Kindbody、Kindlabsの立ち上げにより遺伝子検査を社内で実施
  • メディカバー・ジェネティクスとフィムラボ・ラボラトリーズ、フィンランドで遺伝子検査サービスを提供する提携を発表
  • 米国FertilityとOvationが合併してIVFサービスの大手企業となり、不妊治療サービスへのアクセスが向上
  • ユーロフィンズ・ジェノマ、非侵襲性、胚生検不要、着床前遺伝子異数性スクリーニング検査「niPGT-A」の発売を発表
  • GenEmbryomicsがこれまでで最も包括的なIVF遺伝子検査を導入
  • 体外受精を受けるシンガポール人が、いくつかの種類の治療に新たな資金援助を受ける
  • オーストラリアのフェルティリスが体外受精の胚培養を自動化するため200万米ドルを調達

第15章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. PREIMPLANTATION GENETIC TESTING MARKET RESEARCH PROCESS
• FIGURE 2. PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. PREIMPLANTATION GENETIC TESTING MARKET DYNAMICS
• FIGURE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 20. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. PREIMPLANTATION GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 26. PREIMPLANTATION GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PREIMPLANTATION GENETIC TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY FLUORESCENCE IN-SITU HYBRIDIZATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE-NUCLEOTIDE POLYMORPHISM, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC SCREENING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY ANEUPLOIDY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GENDER IDENTIFICATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY GENDER IDENTIFICATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HLA TYPING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DELETIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DELETIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DUPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY DUPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INVERSIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY INVERSIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TRANSLOCATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TRANSLOCATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY X-LINKED DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY X-LINKED DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CONTRACT RESEARCH & MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CRYOBANKS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY CRYOBANKS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, DIAGNOSTIC LABS, & SERVICE PROVIDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY HOSPITALS, DIAGNOSTIC LABS, & SERVICE PROVIDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 79. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 80. AMERICAS PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 91. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 92. ARGENTINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 103. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 104. BRAZIL PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 105. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 106. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 107. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 108. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 109. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 110. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 111. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 112. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 113. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 114. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 115. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 116. CANADA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 117. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 118. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 119. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 120. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 127. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 128. MEXICO PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 129. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 130. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 131. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 132. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 141. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 142. UNITED STATES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 144. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 146. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 150. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 155. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 156. ASIA-PACIFIC PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 157. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 158. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 159. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 160. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 161. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 162. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 163. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 164. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 165. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 166. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 167. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 168. AUSTRALIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 169. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 170. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 171. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 172. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 173. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 174. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 175. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 176. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 177. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 178. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 179. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 180. CHINA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 181. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 182. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 183. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 184. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 185. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 186. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 187. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 188. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 189. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 190. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 191. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 192. INDIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 193. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 194. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 195. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 196. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 197. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 198. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 199. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 200. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 201. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 202. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 203. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 204. INDONESIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 205. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 206. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 207. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 208. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 209. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 210. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 211. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 212. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 213. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 214. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 215. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 216. JAPAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 217. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 218. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 219. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 220. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 221. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 222. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 223. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 224. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 225. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 226. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 227. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 228. MALAYSIA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 229. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 230. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 231. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 232. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 233. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 234. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 235. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 236. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 237. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 238. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 239. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 240. PHILIPPINES PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 241. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 242. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 243. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 244. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 245. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 246. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 247. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 248. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 249. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 250. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 251. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 252. SINGAPORE PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 260. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 262. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 263. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 264. SOUTH KOREA PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 265. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 266. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 267. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 268. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 269. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 270. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 271. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 272. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 273. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 274. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 275. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 276. TAIWAN PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 277. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 278. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 279. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 280. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 281. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 282. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 283. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 284. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 285. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2018-2023 (USD MILLION)
• TABLE 286. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNORMALITIES, 2024-2030 (USD MILLION)
• TABLE 287. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 288. THAILAND PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 289. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 290. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 291. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
• TABLE 292. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
• TABLE 293. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2018-2023 (USD MILLION)
• TABLE 294. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY PROCEDURE TYPE, 2024-2030 (USD MILLION)
• TABLE 295. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 296. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 297. VIETNAM PREIMPLANTATION GENETIC TESTING MARKET SIZE, BY STRUCTURAL CHROMOSOMAL ABNO

[192 Pages Report] The Preimplantation Genetic Testing Market size was estimated at USD 728.40 million in 2023 and expected to reach USD 829.06 million in 2024, at a CAGR 14.56% to reach USD 1,886.28 million by 2030.

Preimplantation genetic testing (PGT) refers to technologies used to detect chromosomal abnormalities affecting the embryos before implantation. PGT is a crucial service that allows for early detection of genetic abnormalities in embryos before implantation during in-vitro fertilization (IVF) procedures, significantly reducing the risk of passing on inheritable diseases to offspring and improving IVF success rates. The primary application areas for PGT include identifying monogenic disorders, chromosomal abnormalities, mitochondrial diseases, and human leukocyte antigen (HLA) matching for potential siblings. The rising infertility rates due to lifestyle changes and delayed parenthood choices among couples have necessitated the development of PGT technologies. Government initiatives promoting IVF treatments create numerous expansion opportunities. However, high costs associated with IVF treatments and PGT procedures can be a major deterrent to potential end-users. Ethical concerns surrounding PGT and limited insurance coverage for IVF treatments hinder the adoption of PGT services. Major biotechnology companies are rapidly expanding efforts to combat ethical and regulatory challenges and creating technologies that take moral and ethical issues under consideration. New approaches such as next-generation sequencing (NGS) and non-invasive preimplantation testing are emerging technologies that offer significant potential for the growth of the technology.

Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders

Comparative genomic hybridization (CGH) is adopted for detecting chromosomal imbalances by comparing the DNA of two samples. It can detect chromosomal abnormalities in embryos before implantation and help select healthy embryos for IVF. Fluorescence in situ hybridization (FISH) is a technique that uses fluorescent probes to visualize and map specific DNA sequences on chromosomes within cells. It can detect numerical chromosomal abnormalities, including aneuploidy or translocations. Next-generation sequencing (NGS) is a robust tool for preimplantation genetic testing owing to its ability to sequence large amounts of DNA quickly and accurately. Polymerase chain reaction (PCR) is a widely used molecular biology technique that amplifies specific DNA sequences for analysis and can detect monogenic diseases. Single-nucleotide polymorphism (SNP) evaluates variations at the single-nucleotide level within the genome and is used to identify carriers of inherited diseases or assess the risk of multifactorial disorders, including cancer.

Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results

Instruments play a critical role in the PGT process as they enable accurate and efficient genetic screening of embryos. Key instruments include next-generation sequencers (NGS), quantitative PCR (qPCR) systems, and fluorescence in situ hybridization (FISH) analyzers. NGS offers high-throughput sequencing capabilities and a broader detection range, making it suitable for detecting single-gene disorders and chromosomal abnormalities. Reagents and consumables used for PGT consist of various kits, probes, buffers, enzymes, and solutions necessary for genetic testing procedures. Probes are vital in detecting specific chromosomal aberrations, and buffers provide appropriate conditions for optimal amplification conditions. Software and services are essential components of PGT, as they ensure reliable data management, analysis, interpretation, and reporting for genetic testing results. Need-based preferences revolve around user-friendly interfaces, accurate algorithms for variant detection, comprehensive databases for variant annotation, and secure data storage options.

Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders

Preimplantation genetic diagnosis (PGD) is a specialized procedure that allows the identification of genetic mutations or chromosomal abnormalities in embryos diagnosed before implantation and pregnancy. The primary goal of PGD is to reduce the risk of developing specific genetic disorders such as cystic fibrosis, Huntington's disease, and muscular dystrophy. Preimplantation genetic screening (PGS), referred to as preimplantation genetic testing for aneuploidies (PGT-A), detects chromosomal aneuploidies or imbalances in embryos before implantation. PGS aims to improve the chances of successful pregnancies by identifying embryos with the correct number of chromosomes, reducing the risk of miscarriage, stillbirth, or having a child affected by Down syndrome or other chromosomal abnormalities.

Application: Wide use of preimplantation genetic testing for aneuploidy disorder

Aneuploidy is a disorder in which an abnormal number of chromosomes in a cell leads to genetic disorders, including Down syndrome, Edwards syndrome, and Patau syndrome. Preimplantation of genetic testing for aneuploidy (PGT-A) identifies embryos with chromosomal abnormalities before implantation, increasing the chances of a successful pregnancy outcome. Gender identification through preimplantation genetic testing allows couples to choose the gender of their child for family balancing or to avoid sex-linked disorders. Human leukocyte antigen (HLA) typing matches tissue types between donor and recipient for stem cell or organ transplantation procedures. Preimplantation HLA typing identifies embryos with compatible tissue types, potentially facilitating successful transplants in siblings with blood disorders or immune system deficiencies. Structural chromosomal abnormalities involve alterations in chromosome structure, including deletions, duplications, and rearrangements. In addition, X-linked diseases are caused by mutations in genes on the X chromosome, affecting males more severely than females.

End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments

Preimplantation genetics testing is widely used in various healthcare facilities, providing successful outcomes in clinical research. Contract research and manufacturing organizations (CRMOs) are primary organizations that play a crucial role in developing, manufacturing, and commercializing preimplantation genetic testing products. These organizations prefer outsourcing their services to ensure quality control, compliance with regulatory standards, and cost efficiency while focusing on their core competencies. Similarly, cryobanks are institutions that store biological samples such as sperm, eggs, and embryos at extremely low temperatures for future use. Preimplantation genetic testing is crucial for cryobanks to ensure the genetic viability of stored samples before implantation procedures like IVF or ICSI. Hospitals, diagnostic labs, and service providers contribute to patient care through accurate diagnosis and effective treatments using preimplantation genetic testing technologies. Research laboratories and academic institutes play a vital role in driving innovation and advancements in preimplantation genetic testing through cutting-edge research, technological developments, and interdisciplinary collaborations. These institutions focus on developing novel techniques like next-generation sequencing (NGS) to enhance the accuracy of preimplantation genetic testing methods.

Regional Insights

The Americas exhibit a high need for preimplantation genetic testing (PGT) owing to rising infertility rates caused by lifestyle changes and increasing awareness regarding genetic testing. Well-established healthcare infrastructure facilities and favorable reimbursement policies have made PGT services more accessible to couples seeking infertility treatments in the Americas. Companies in the region have strong R&D capabilities and government support that drive innovation in the field. Asia is emerging as a big and opportunistic market for PGT owing to improved provision of advanced fertility techniques such as IVF with PGT services and growing medical tourism, attracting international patients seeking cost-effective treatment options. Europe contributes significantly to the global PGT market due to factors such as increased government funding for healthcare research and widespread adoption of IVF procedures across various European countries. Moreover, stringent regulatory frameworks surrounding genetic testing ensure quality control and ethical considerations when implementing PGT services. Key players within this region contribute significantly to technological advancements in preimplantation genetic testing practices.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Preimplantation Genetic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Preimplantation Genetic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Preimplantation Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Preimplantation Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Comparative Genomic Hybridization
  • Fluorescence in-Situ Hybridization
  • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Single-Nucleotide Polymorphism

• Offering
  • Instruments
  • Reagents & Consumables
  • Software & Services

• Procedure Type
  • Preimplantation Genetic Diagnosis
  • Preimplantation Genetic Screening

• Application
  • Aneuploidy
  • Gender Identification
  • HLA Typing
  • Single Gene Disorders
  • Structural Chromosomal Abnormalities
    • Deletions
    • Duplications
    • Inversions
    • Translocations

• X-Linked Disorders

• End User
  • Contract Research & Manufacturing Organizations
  • Cryobanks
  • Hospitals, Diagnostic Labs, & Service Providers
  • Research Laboratories & Academic Institutes

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Preimplantation Genetic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Preimplantation Genetic Testing Market?

3. What are the technology trends and regulatory frameworks in the Preimplantation Genetic Testing Market?

4. What is the market share of the leading vendors in the Preimplantation Genetic Testing Market?

5. Which modes and strategic moves are suitable for entering the Preimplantation Genetic Testing Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
    • 5.1.1.2. Increase in the rate of infertility and the rising number of fertility clinics worldwide
    • 5.1.1.3. Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Limitation and risks associated with PGT
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancement in the field of preimplantation genetic analysis
    • 5.1.3.2. Emerging startup ecosystem and investments in the field of preimplantation genetic testing
  • 5.1.4. Challenges
    • 5.1.4.1. Ethical constraints and Misuse of PGT
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders
  • 5.2.2. Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results
  • 5.2.3. Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders
  • 5.2.4. Application: Wide use of preimplantation genetic testing for aneuploidy disorder
  • 5.2.5. End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments
• 5.3. Market Trend Analysis
  • 5.3.1. Presence of established companies and startups launching innovative preimplantation genetic solutions across the Americas
  • 5.3.2. Supportive Government initiatives and the increasing infertility rate emphasized preimplantation genetic testing adoption in APAC
  • 5.3.3. Rising adoption of preimplantation genetic testing for IVF across Europe and potential of global player expansion in Middle East & Africa
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis

6. Preimplantation Genetic Testing Market, by Technology

• 6.1. Introduction
• 6.2. Comparative Genomic Hybridization
• 6.3. Fluorescence in-Situ Hybridization
• 6.4. Next-Generation Sequencing
• 6.5. Polymerase Chain Reaction
• 6.6. Single-Nucleotide Polymorphism

7. Preimplantation Genetic Testing Market, by Offering

• 7.1. Introduction
• 7.2. Instruments
• 7.3. Reagents & Consumables
• 7.4. Software & Services

8. Preimplantation Genetic Testing Market, by Procedure Type

• 8.1. Introduction
• 8.2. Preimplantation Genetic Diagnosis
• 8.3. Preimplantation Genetic Screening

9. Preimplantation Genetic Testing Market, by Application

• 9.1. Introduction
• 9.2. Aneuploidy
• 9.3. Gender Identification
• 9.4. HLA Typing
• 9.5. Single Gene Disorders
• 9.6. Structural Chromosomal Abnormalities
• 9.7. X-Linked Disorders

10. Preimplantation Genetic Testing Market, by End User

• 10.1. Introduction
• 10.2. Contract Research & Manufacturing Organizations
• 10.3. Cryobanks
• 10.4. Hospitals, Diagnostic Labs, & Service Providers
• 10.5. Research Laboratories & Academic Institutes

11. Americas Preimplantation Genetic Testing Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Preimplantation Genetic Testing Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Preimplantation Genetic Testing Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Thermo Fisher Unveils Ion ReproSeq PGT-A Kit and Ion AmpliSeq Polyploidy Kit
  • 14.3.2. Kindbody Brings Genetic Testing In-House with the Launch of Kindlabs
  • 14.3.3. Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
  • 14.3.4. U.S. Fertility and Ovation Combine to Create IVF Services Powerhouse, Increasing Access to Fertility Services
  • 14.3.5. Eurofins Genoma Announces Launch of niPGT-A, a Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening
  • 14.3.6. GenEmbryomics Introduces the Most Complete IVF Genetic Test Ever Made Available
  • 14.3.7. Singaporeans Undergoing IVF to Get New Funding For Some Types of Preimplantation Genetic Testing
  • 14.3.8. Australia's Fertilis Raised USD 2 Million to Automate IVF Embryo Culturing

15. Competitive Portfolio

• 15.1. Key Company Profiles
• 15.2. Key Product Portfolio